Veracyte Operating Margin from 2010 to 2024
| VCYT Stock | USD 42.95 0.06 0.14% |
Check Veracyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Veracyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 28.5 M, Interest Expense of 14.2 K or Selling General Administrative of 165.5 M, as well as many indicators such as Price To Sales Ratio of 5.26, Dividend Yield of 0.0 or PTB Ratio of 1.82. Veracyte financial statements analysis is a perfect complement when working with Veracyte Valuation or Volatility modules.
Veracyte | Operating Margin |
Latest Veracyte's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Veracyte over the last few years. It is Veracyte's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Veracyte's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.11 % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Veracyte Operating Margin Regression Statistics
| Arithmetic Mean | (1.21) | |
| Coefficient Of Variation | (156.62) | |
| Mean Deviation | 1.27 | |
| Median | (0.37) | |
| Standard Deviation | 1.89 | |
| Sample Variance | 3.59 | |
| Range | 5.646 | |
| R-Value | 0.71 | |
| Mean Square Error | 1.89 | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | 0.30 | |
| Total Sum of Squares | 50.25 |
Veracyte Operating Margin History
About Veracyte Financial Statements
Veracyte shareholders use historical fundamental indicators, such as Operating Margin, to determine how well the company is positioned to perform in the future. Although Veracyte investors may analyze each financial statement separately, they are all interrelated. The changes in Veracyte's assets and liabilities, for example, are also reflected in the revenues and expenses on on Veracyte's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Veracyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 761 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.